Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip J Clements

Showing results (61-70 of 93) with videos related to

Pageof 10
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|April 5, 2017
Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and IIElizabeth R Volkmann, Donald P Tashkin, Ning Li, et al.
Rheumatology (Oxford, England)|December 21, 2013
Prevalence of subclinical atherosclerosis is increased in systemic sclerosis and is associated with serum proteins: a cross-sectional, controlled study of carotid ultrasoundElena Schiopu, Karen M Au, Maureen A McMahon, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 15, 2014
Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung diseaseElizabeth R Volkmann, Rajeev Saggar, Dinesh Khanna, et al.
ACR Open Rheumatology|December 5, 2020
Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and IIElizabeth R Volkmann, Virginia Steen, Ning Li, et al.
The Journal of Rheumatology|February 17, 2019
Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and IIElizabeth R Volkmann, Donald P Tashkin, Myung Sim, et al.
Seminars in Arthritis and Rheumatism|September 9, 2020
The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosisElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
Chest|December 26, 2016
Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study IIDonald P Tashkin, Elizabeth R Volkmann, Chi-Hong Tseng, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 11, 2016
Association of Systemic Sclerosis With a Unique Colonic Microbial ConsortiumElizabeth R Volkmann, Yu-Ling Chang, Nashla Barroso, et al.
Rheumatology (Oxford, England)|August 16, 2014
Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standardsDinesh Khanna, Daniel E Furst, Yannick Allanore, et al.
Chest|July 22, 2008
High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung diseaseJonathan G Goldin, David A Lynch, Diane C Strollo, et al.
Pageof 10

Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Arthritis & Rheumatology (Hoboken, N.J.)|April 5, 2017
Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and IIElizabeth R Volkmann, Donald P Tashkin, Ning Li, et al.
Rheumatology (Oxford, England)|December 21, 2013
Prevalence of subclinical atherosclerosis is increased in systemic sclerosis and is associated with serum proteins: a cross-sectional, controlled study of carotid ultrasoundElena Schiopu, Karen M Au, Maureen A McMahon, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 15, 2014
Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung diseaseElizabeth R Volkmann, Rajeev Saggar, Dinesh Khanna, et al.
ACR Open Rheumatology|December 5, 2020
Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and IIElizabeth R Volkmann, Virginia Steen, Ning Li, et al.
The Journal of Rheumatology|February 17, 2019
Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and IIElizabeth R Volkmann, Donald P Tashkin, Myung Sim, et al.
Seminars in Arthritis and Rheumatism|September 9, 2020
The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosisElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
Chest|December 26, 2016
Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study IIDonald P Tashkin, Elizabeth R Volkmann, Chi-Hong Tseng, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 11, 2016
Association of Systemic Sclerosis With a Unique Colonic Microbial ConsortiumElizabeth R Volkmann, Yu-Ling Chang, Nashla Barroso, et al.
Rheumatology (Oxford, England)|August 16, 2014
Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standardsDinesh Khanna, Daniel E Furst, Yannick Allanore, et al.
Chest|July 22, 2008
High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung diseaseJonathan G Goldin, David A Lynch, Diane C Strollo, et al.
Pageof 10